| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 04/14/2005 | WO2005032472A2 Pyrrolidine and piperidine derivatives as factor xa inhibitors |
| 04/14/2005 | WO2005032471A2 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
| 04/14/2005 | WO2005032470A2 Compositions and methods for treating burns |
| 04/14/2005 | WO2005032469A2 METHODS FOR REGULATING BUD-HYPHA TRANSITION AND cAMP LEVELS IN CANDIDA ALBICANS |
| 04/14/2005 | WO2005032468A2 Monocyclic and bicyclic lactams as factor xa inhibitors |
| 04/14/2005 | WO2005032466A2 Calcium phosphate-based materials containig zinc, magnesium, fluoride and carbonate |
| 04/14/2005 | WO2005032465A2 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| 04/14/2005 | WO2005032464A2 Phenyl pyrrolidine ether tachykinin receptor antagonists |
| 04/14/2005 | WO2005032461A2 Novel peptide with osteogenic activity |
| 04/14/2005 | WO2005032460A2 Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
| 04/14/2005 | WO2005032458A2 Dye solution and method for detecting anhydrous ammonia |
| 04/14/2005 | WO2005032457A2 Vectors and methods for immunization against norwalk virus using transgenic plants |
| 04/14/2005 | WO2005032455A2 Combinatorially selected phosphorodithioate aptamer targeting ap-1 |
| 04/14/2005 | WO2005032454A2 Anti-muc-1 single chain antibodies for tumor targeting |
| 04/14/2005 | WO2005032453A2 Antiviral agents for the treatment, control and prevention of infections by coronaviruses |
| 04/14/2005 | WO2005018579A3 Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives and vicinal cyano, hydroxy substituted carboxylic acid esters |
| 04/14/2005 | WO2005016286A8 Pyrazine modulators of cannabinoid receptors |
| 04/14/2005 | WO2005016275A3 Formulations containing an immune response modifier |
| 04/14/2005 | WO2005016253A3 Formula nd method for the delivery of oral medications to animals |
| 04/14/2005 | WO2005013892A9 Hydrolytically-resistant boron-containing therapeutics and methods of use |
| 04/14/2005 | WO2005007111A3 Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| 04/14/2005 | WO2005007099A3 Pkb inhibitors as anti-tumor agents |
| 04/14/2005 | WO2005007081A3 Compounds and methods for delivery of prostacyclin analogs |
| 04/14/2005 | WO2005007075A3 Adaptive resynchronization therapy system |
| 04/14/2005 | WO2005004806A3 Combination therapy for treating chronic inflammatory diseases |
| 04/14/2005 | WO2005002514A3 Compounds having inhibitibe activity of phosphatidylinositol 3-kinase and methods of use thereof |
| 04/14/2005 | WO2005002512A3 Immunotherapeutic vaccine strategy |
| 04/14/2005 | WO2005002503A3 Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| 04/14/2005 | WO2005000247A3 4-carboxamido quinoline derivatives for use as nk-2 and nk-3 |
| 04/14/2005 | WO2005000196A3 Inhibition of egr-1 expression by rpar-ϝ agonista and related compositions and methods |
| 04/14/2005 | WO2005000194A3 Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
| 04/14/2005 | WO2004112706A3 Vaccines, immunotherapeutics and methods for using the same |
| 04/14/2005 | WO2004112699A3 Mitotic kinesin inhibitors |
| 04/14/2005 | WO2004110374A3 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| 04/14/2005 | WO2004110373A3 Therapeutic vaccine compositions for the treatment of type 1 diabetes |
| 04/14/2005 | WO2004110348A3 Saururus cernuus compounds that inhibit cellular responses to hypoxia |
| 04/14/2005 | WO2004110342A3 Novel polymorph of gabapentin and its conversion to gabapentin form-ii |
| 04/14/2005 | WO2004108061A3 Stable injectable pharmaceutical composition of thiopental; method for stabilizing aqueous solutions of thiopental and, use of thiopental for producing a medicament |
| 04/14/2005 | WO2004105700A3 Compounds, methods and pharmaceutical compositions for inhibiting parp |
| 04/14/2005 | WO2004100891A3 Cytotoxic indeno and isoindoloisoquinolones |
| 04/14/2005 | WO2004098487A3 Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 5 (tmprss5) |
| 04/14/2005 | WO2004096146A3 Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage |
| 04/14/2005 | WO2004096123A3 Methods of promoting cell viability |
| 04/14/2005 | WO2004092124A3 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
| 04/14/2005 | WO2004091543A3 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
| 04/14/2005 | WO2004091542A3 Nitrogen containing integrin targeting compounds |
| 04/14/2005 | WO2004075848A3 Antitumor inhibitors and use thereof |
| 04/14/2005 | WO2004073636A3 Compositions comprising a polysaccharide component and one or more coating layers |
| 04/14/2005 | WO2004073624A3 Contraceptive methods and compositions related to proteasomal interference |
| 04/14/2005 | WO2004071427A3 Screening and treatment methods for prevention of preterm delivery |
| 04/14/2005 | WO2004060293A3 Methods and compositions for protection against thrombolysis-associated reperfusion injury |
| 04/14/2005 | WO2004047767A3 Methods for identifying risk of breast cancer and treatments thereof |
| 04/14/2005 | WO2004037205A8 LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL |
| 04/14/2005 | WO2004030612A3 Light emitting diode, support & method of manufacture |
| 04/14/2005 | WO2004026228A3 Method for reducing morbidity and mortality in critically ill patients |
| 04/14/2005 | US20050080245 basification of water insoluble chitins, then rinsing, acetylating, dissolving in aqueous solution containing surfactants, adjusting the pH, mixing with water-miscible solvents, precipitation, separating and washing the water-soluble pharmaceutically acceptable chitins |
| 04/14/2005 | US20050080092 Such as N-(6-aminohexyl)-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine Dihydrochloride; for hydration of mucosal surfaces, treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, esophogitis, emphysema, and pneumonia |
| 04/14/2005 | US20050080084 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage |
| 04/14/2005 | US20050080075 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms |
| 04/14/2005 | US20050080066 Antiglucocorticoids for the treatment of catatonia |
| 04/14/2005 | US20050080061 inhibit the binding of cortisol to its receptors; Mifepristone; dexamethasone and betamethasone |
| 04/14/2005 | US20050080055 Method of treating breast cancer with androgen receptor antagonists |
| 04/14/2005 | US20050079558 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders |
| 04/14/2005 | US20050079214 Capsules; swalling with liquid |
| 04/14/2005 | US20050079178 Inhibitor of cardiac tachyarrhythmias |
| 04/14/2005 | US20050079169 Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| 04/14/2005 | US20050077459 Radiation phantom |
| 04/14/2005 | CA2581940A1 Methods, compositions,, apparatuses containing tetrameric oxygen |
| 04/14/2005 | CA2540894A1 Gene expression profiles and methods of use |
| 04/14/2005 | CA2540890A1 Treatment of demyelinating autoimmune disease with modified ordered peptides |
| 04/14/2005 | CA2540809A1 Lpa receptor agonists and antagonists and methods of use |
| 04/14/2005 | CA2540764A1 In vivo efficacy of ny-eso-1 plus adjuvant |
| 04/14/2005 | CA2540742A1 Compositions and methods for treating burns |
| 04/14/2005 | CA2540703A1 Methods and compositions for mycoplasma pneumoniae exotoxins |
| 04/14/2005 | CA2540699A1 Polysaccharides for pulmonary delivery of active agents |
| 04/14/2005 | CA2540665A1 Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
| 04/14/2005 | CA2540452A1 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
| 04/14/2005 | CA2540061A1 Phenyl pyrrolidine ether tachykinin receptor antagonists |
| 04/14/2005 | CA2539438A1 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| 04/14/2005 | CA2526690A1 Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors |
| 04/14/2005 | CA2524209A1 Antiviral agents for the treatment, control and prevention of infections by coronaviruses |
| 04/14/2005 | CA2515583A1 Hydrolases, nucleic acids encoding them and methods for making and using them |
| 04/14/2005 | CA2508007A1 Dye solutions for use in methods to detect the prior evaporation of anhydrous ammonia and the production of illicit drugs |
| 04/13/2005 | EP1521743A1 Hmg-coa reductase inhibitors |
| 04/13/2005 | CN1606548A Aryloxyphenyl and arylsulfanylphenyl piperazine derivatives |
| 04/13/2005 | CN1606452A Liquid composition of modified factor vii polypeptides |
| 04/13/2005 | CN1606437A Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
| 04/13/2005 | CN1196741C Texturized cellulosic and lignocellulosic materials and compsns. and composites made thereform |
| 04/13/2005 | CN1196681C (+)-Norcisapride useful for 5-HT3 and 5-HT4 mediated disorbers |
| 04/13/2005 | CN1196671C Mono-and-disubstituted 2-pyrolyl gamma-aminobutric acids |
| 04/13/2005 | CN1196488C Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 04/13/2005 | CN1196467C Oral composition |
| 04/13/2005 | CN1196465C Monoglyceryl or polyglyceryl fatty alcohol, special polyol and oxidizing dye composition for keratin fiber |
| 04/12/2005 | US6878757 Caprolactone copolymer; alkali metal stearoyl, palmitoyl, or oleoyl lactylate; may also contain silver stearoyl lactylate |
| 04/12/2005 | US6878739 Composition for treating or preventing glomerulopathy |
| 04/12/2005 | US6878722 Substituted cycloalkyl P1′ hepatitis C virus inhibitors |
| 04/12/2005 | US6878720 VEGF receptor tyrosine kinase inhibitors |
| 04/12/2005 | US6878717 HIV replication inhibiting pyrimidines |
| 04/12/2005 | CA2293247C 4-phenylpiperidine compounds |
| 04/12/2005 | CA2131229C Bisconjugates comprising two saccharides and a spacer |